These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 9607576

  • 21. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX, Marshall JL, Ness E, Martin RR, Dvorchik B, Rizvi N, Marquis J, McKinlay M, Dahut W, Hawkins MJ.
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [Abstract] [Full Text] [Related]

  • 22. Phase II study of combination thalidomide/interleukin-2 therapy plus granulocyte macrophage-colony stimulating factor in patients with metastatic renal cell carcinoma.
    Amato RJ, Malya R, Rawat A.
    Am J Clin Oncol; 2008 Jun; 31(3):237-43. PubMed ID: 18525301
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A phase II trial of methotrexate-human serum albumin (MTX-HSA) in patients with metastatic renal cell carcinoma who progressed under immunotherapy.
    Vis AN, van der Gaast A, van Rhijn BW, Catsburg TK, Schmidt C, Mickisch GH.
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):342-5. PubMed ID: 11914915
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
    Portielje JE, Lamers CH, Kruit WH, Sparreboom A, Bolhuis RL, Stoter G, Huber C, Gratama JW.
    Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group.
    Tourani JM, Pfister C, Tubiana N, Ouldkaci M, Prevot G, Lucas V, Oudard S, Malet M, Cottu P, Ferrero JM, Mayeur D, Rixe O, Sun XS, Bernard O, Andre T, Tournigand C, Muracciole X, Guilhot J, Subcutaneous Administration Propeukin Program Cooperative Group.
    J Clin Oncol; 2003 Nov 01; 21(21):3987-94. PubMed ID: 14581421
    [Abstract] [Full Text] [Related]

  • 33. A phase I and pharmacokinetic study of squalamine, a novel antiangiogenic agent, in patients with advanced cancers.
    Bhargava P, Marshall JL, Dahut W, Rizvi N, Trocky N, Williams JI, Hait H, Song S, Holroyd KJ, Hawkins MJ.
    Clin Cancer Res; 2001 Dec 01; 7(12):3912-9. PubMed ID: 11751482
    [Abstract] [Full Text] [Related]

  • 34. TH1/TH2 serum cytokine profiles and soluble TNF-receptor response in patients with chronic hepatitis C during recombinant human interleukin-12 (rHuIL-12) treatment.
    Teuber G, Rossol S, Lee JH, Dietrich CF, Zeuzem S.
    Z Gastroenterol; 2002 Jul 01; 40(7):487-95. PubMed ID: 12122596
    [Abstract] [Full Text] [Related]

  • 35. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
    Alatrash G, Hutson TE, Molto L, Richmond A, Nemec C, Mekhail T, Elson P, Tannenbaum C, Olencki T, Finke J, Bukowski RM.
    J Clin Oncol; 2004 Jul 15; 22(14):2891-900. PubMed ID: 15254058
    [Abstract] [Full Text] [Related]

  • 36. Phase I/II trial of human recombinant interferon gamma in renal cell carcinoma.
    Rinehart JJ, Malspeis L, Young D, Neidhart JA.
    J Biol Response Mod; 1986 Aug 15; 5(4):300-8. PubMed ID: 3090208
    [Abstract] [Full Text] [Related]

  • 37. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
    van Herpen CM, Jansen RL, Kruit WH, Hoekman K, Groenewegen G, Osanto S, De Mulder PH.
    Br J Cancer; 2000 Feb 15; 82(4):772-6. PubMed ID: 10732744
    [Abstract] [Full Text] [Related]

  • 38. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M, Fujimura M, Kawamura K, Suzuki S, Hamano M, Nishikawa Y, Nagayama T.
    Int J Urol; 2005 May 15; 12(5):442-8. PubMed ID: 15948742
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.